LONDON, Sept 24, 2012 /PRNewswire/ -- Lightlake
Therapeutics Inc. (OTCBB: LLTP) (the "Company" or "Lightlake"), an
early stage biopharmaceutical company developing modern addiction
treatments based on its expertise using opioid antagonists,
announced today that it has appointed former US Food and Drug
Administration Commissioner, Dr. David
Kessler, as a strategic advisor.
Dr. Kessler was the FDA Commissioner under presidents
George H. W. Bush and Bill Clinton, where he directed a number of new
programs including the regulation of marketing and sale of tobacco
products to children and nutrition labeling for food. He is a
graduate of Amherst College, the
University of Chicago Law School, and
Harvard Medical School, and has been
the dean of the medical schools at Yale
and the University of California, San
Francisco. He currently serves on the board of various
organizations including the National Center for Addiction and
Substance Abuse at Columbia University
as well as Drug Strategies, a non-profit research institute that
promotes more effective drug abuse prevention, education and
treatment.
"We are very pleased to add Dr. Kessler as a strategic advisor,"
said Dr. Roger Crystal, Chief
Executive Officer of Lightlake. "With his wide range of experience
in research, clinical medicine, education, administration, and law,
Dr. Kessler will be a tremendous guide for us as we work to develop
a range of treatments to common addictive disorders. Specifically,
Dr. Kessler's major involvement with us will be to advise on the
side-effects of addiction."
Dr. Kessler is also the author of "The End of Overeating: Taking
Control of the Insatiable American Appetite," which examines how
our bodies and minds are changed when we consume foods that contain
sugar, fat, and salt. Last month, Lightlake reported positive final
data from a Phase II study of the Company's proprietary opioid
antagonist naloxone nasal spray treatment for patients with Binge
Eating Disorder (BED), which is the most chronic and common of all
eating disorders. Patients suffering from BED typically exhibit a
lack of control eating foods typically high in sugar, fat or salt,
are preoccupied with eating these types of foods, and are able to
override the feeling of fullness.
About Lightlake Therapeutics Inc.
Lightlake Therapeutics Inc. is a developing biopharmaceutical
company aiming to build a platform of biopharmaceutical solutions
to common addictions and related disorders. Currently, the Company
is focused on providing a safe, effective and simple treatment for
patients who are obese or overweight as a result of Binge Eating
Disorder in addition to those patients suffering from Bulimia
Nervosa. Lightlake recently acquired patents that will allow it to
widen its product pipeline to address patients with addictions to
opioid painkillers, methadone, cocaine and amphetamine. The Company
anticipates launching a development program for each of these
purposes in the future.
Safe Harbor
This press release contains forward-looking statements. These
statements relate to future events or our future financial
performance and involve known and unknown risks, uncertainties and
other factors that may cause our or our industry's actual results,
levels of activity, performance or achievements to be materially
different from any future results, levels of activity, performance
or achievements expressed, implied or inferred by these
forward-looking statements. In some cases, you can identify
forward-looking statements by terminology such as "may," "will,"
"should," "could," "would," "expects," "plans," "intends,"
"anticipates," "believes," estimates," "predicts," "projects,"
"potential" or "continue" or the negative of such terms and other
comparable terminology. These statements are only predictions based
on our current expectations and projections about future events.
You should not place undue reliance on these statements. Actual
events or results may differ materially. In evaluating these
statements, you should specifically consider various factors. These
and other factors may cause our actual results to differ materially
from any forward- looking statement. We undertake no obligation to
update any of the forward-looking statements after the date of this
presentation to conform those statements to reflect the occurrence
of unanticipated events, except as required by applicable law.
Contact:
Investor
Mr. Kevin Fickle
President
NUWA Group LLC
Tel: +1-925-330-8315
Email: kevin@nuwagroup.com
Company
Dr. Roger Crystal
Lightlake Therapeutics Inc.
Tel: +44(0)-203-617-8739
Email: roger.crystal@lightlaketherapeutics.com
SOURCE Lightlake Therapeutics Inc.